In BOLERO‐3, addition of everolimus to trastuzumab plus vinorelbine significantly prolongs progression‐free survival compared with placebo in patients with trastuzumab‐resistant and taxane‐pretreated, ErbB2‐positive, advanced breast cancer 40. Here, ERBB2 is linked to breast cancer.